8-K: Apyx Medical Announces Positive Clinical Study Results for Renuvion in Body Contouring

Apyx Medical reports favorable clinical outcomes and safety data from two peer-reviewed studies evaluating Renuvion's use in abdominal body contouring procedures, including lipoabdominoplasty.

Summary

• Apyx Medical Corporation announced the publication of two peer-reviewed clinical studies on Renuvion's use in body contouring procedures.
• The studies evaluated Renuvion during procedures that included lipoabdominoplasty.
• The first study, a prospective, randomized controlled trial, showed improvements in abdominal skin laxity and higher patient satisfaction scores with Renuvion.
• The second study, a retrospective analysis, found no statistically significant difference in adverse events with or without Renuvion, even with more concurrent procedures and longer surgical times in the Renuvion group.
• Apyx Medical estimates over 15 million patients are using GLP-1 drugs, potentially driving demand for treatments addressing loose and lax skin.
• Renuvion is the only FDA-cleared device for addressing loose and lax skin post-liposuction in aesthetic body contouring procedures.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and market positioning, suggesting a favorable outlook for Apyx Medical and Renuvion. The sentiment is optimistic due to the potential for increased demand and the device's unique FDA clearance.

Positives

• Clinical studies show favorable outcomes and safety data for Renuvion in body contouring.
• Renuvion improves abdominal skin laxity and patient satisfaction after lipoabdominoplasty.
• The use of Renuvion does not increase complication rates.
• Apyx Medical is positioned to benefit from the growing demand for skin tightening procedures due to rapid weight loss from GLP-1 drugs.
• Renuvion has FDA clearance for addressing loose and lax skin post-liposuction.

Risks

• The company's future performance is subject to risks and uncertainties related to regulatory approvals, supply chain disruptions, economic conditions, and litigation.
• The company's ability to gain requisite approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally, could impact future results.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions, could impact future results.
• Changes in general economic, business or demographic conditions or trends could impact future results.
• Changes in and effects of the geopolitical environment could impact future results.
• Liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes or investigations could impact future results.

Future Outlook

The company anticipates growth in patients seeking treatment for loose and lax skin due to rapid weight loss from GLP-1 drugs, positioning Renuvion to address this growing patient population.

Management Comments

• Charlie Goodwin, President and Chief Executive Officer of Apyx Medical, stated that Renuvion is uniquely positioned to treat the growing patient population seeking treatment for loose and lax skin due to rapid weight loss.
• Charlie Goodwin stated that the newly published studies reinforce the growing body of evidence supporting the safety and value of Renuvion in aesthetic body contouring.

Industry Context

The announcement highlights the growing demand for body contouring procedures, particularly driven by the increasing use of GLP-1 drugs for weight loss. Apyx Medical is positioning Renuvion as a key solution for addressing the resulting skin laxity, capitalizing on this trend in the aesthetic surgery market.

Comparison to Industry Standards

• The studies compare Renuvion-assisted lipoabdominoplasty to traditional lipoabdominoplasty, demonstrating improved outcomes in skin laxity and patient satisfaction.
• The company claims Renuvion is the only FDA-cleared device for addressing loose and lax skin post-liposuction, suggesting a competitive advantage over other energy-based devices or surgical techniques.
• Comparable companies in the aesthetic device market include those offering energy-based skin tightening solutions, such as Thermage (Solta Medical) and BodyTite (InMode), although Renuvion's helium plasma technology offers a unique approach.

Stakeholder Impact

• Shareholders may react positively to the favorable clinical data and market opportunity.
• Surgeons gain further evidence supporting the use of Renuvion in body contouring procedures.
• Patients benefit from improved outcomes and satisfaction with Renuvion-assisted procedures.

Key Dates

Keywords

Renuvion, Apyx Medical, Body Contouring, Lipoabdominoplasty, Skin Laxity, GLP-1 Drugs, Aesthetic Surgery, Clinical Studies